Thursday, June 11, 2026

Intelligence Β· INN directory

Pharmaceutical Drugs

Regulatory status, brand names, and pipeline context for BD, medical affairs, and competitive intelligence teams.

Drugs indexed 4,797
Companies 1,769
Pipeline programs 20,548

Quick answer

NovaPharmaNews tracks 4,797 pharmaceutical drugs by INN (International Nonproprietary Name), with US FDA approval status, brand names, originators, routes of administration, and links to pipeline programs and patents. Search by generic name or browse A–Z for competitive intelligence and medical affairs reference.

Showing page 129 of 200 Β· By data quality, then INN

  1. leniolisib

    JOENJA

    EMA: unknown

  2. lenvatinib

    LENVIMA Eisai Co.,

    EMA: approved Β· TGA: approved Β· NMPA: clinical trials

    L01XE29
  3. lepirudin

    REFLUDAN

    EMA: withdrawn

    B01AE02
  4. leriglitazone

    NEZGLYAL

    EMA: refused

    A16AX23
  5. leuprorelin

    ELIGARD 1 MONTH AbbVie

    EMA: approved Β· TGA: approved

  6. levacetylmethadol

    ORLAAM

    EMA: withdrawn

    N02AC
  7. linzagolix choline

    YSELTY

    EMA: approved

    H01CC04
  8. lisocabtagene maraleucel

    BREYANZI

    EMA: approved

    L01XL08
  9. lisuride

    NENAD

    EMA: application withdrawn

  10. lomitapide

    LOJUXTA

    EMA: approved

    C10AX12
  11. lonapegsomatropin

    SKYTROFA (PREVIOUSLY LONAPEGSOMATROPIN ASCENDIS PHARMA)

    EMA: approved

    H01AC09
  12. loncastuximab tesirine

    ZYNLONTA

    EMA: approved

    L01FX22
  13. lonoctocog alfa

    AFSTYLA

    EMA: approved Β· PMDA: approved

    B02BD02
  14. lurasidone

    APO-LURASIDONE Alphapharm Pty Ltd

    EMA: approved Β· TGA: approved

    N05AE05
  15. luspatercept

    REBLOZYL

    EMA: approved

    B03XA06
  16. lutetium (177lu) chloride

    ENDOLUCINBETA

    EMA: approved

    V10X
  17. lutetium (177lu) oxodotreotide

    LUTATHERA

    EMA: approved

    V10XX04
  18. lutetium (177lu) vipivotide tetraxetan

    PLUVICTO

    EMA: approved

    V10XX
  19. lutropin alfa

    LUVERIS Merck KGaA, Darmstadt, Germany

    EMA: approved Β· TGA: approved

    G03GA07
  20. macimorelin

    GHRYVELIN (PREVIOUSLY MACIMORELIN AETERNA ZENTARIS)

    EMA: approved

    V04CD06
  21. mangafodipir

    TESLASCAN

    EMA: withdrawn

    V08CA05
  22. maralixibat

    LIVMARLI

    EMA: application withdrawn

    A05AX
  23. marstacimab

    HYMPAVZI

    EMA: approved Β· PMDA: approved

    B02BX11
  24. masitinib

    MASITINIB AB SCIENCE

    EMA: refused

    L01EX06

Frequently asked questions

What is the NovaPharmaNews drugs directory?

It is a searchable index of 4,797 pharmaceutical active ingredients and their marketed profiles β€” INN, brand names, US regulatory status, manufacturers, and cross-links to clinical pipeline and patent records.

Where does drug approval data come from?

Profiles combine FDA Drugs@FDA and Orange Book references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence. This directory is for professional reference, not medical advice.

How do I find a drug by brand name?

Use the search box on this page β€” it matches both INN (generic name) and slug. Brand names appear on each drug row and on the full drug profile page, with links to the originator company when available.